MX2020013362A - Metodos para la liberacion de cromolina. - Google Patents

Metodos para la liberacion de cromolina.

Info

Publication number
MX2020013362A
MX2020013362A MX2020013362A MX2020013362A MX2020013362A MX 2020013362 A MX2020013362 A MX 2020013362A MX 2020013362 A MX2020013362 A MX 2020013362A MX 2020013362 A MX2020013362 A MX 2020013362A MX 2020013362 A MX2020013362 A MX 2020013362A
Authority
MX
Mexico
Prior art keywords
methods
cromolyn
delivering
delivering cromolyn
aliergic
Prior art date
Application number
MX2020013362A
Other languages
English (en)
Inventor
Alex Franzusoff
David R Elmaleh
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2020013362A publication Critical patent/MX2020013362A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para liberar cromolina a un paciente en necesidad del mismo, métodos de tratamiento de las afecciones amiloideas asociadas y enfermedades inflamatorias o alergias pulmonares y empaques de burbuja y kits que comprenden cromolina.
MX2020013362A 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina. MX2020013362A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826798P 2013-05-23 2013-05-23

Publications (1)

Publication Number Publication Date
MX2020013362A true MX2020013362A (es) 2021-03-09

Family

ID=52144109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016102A MX2015016102A (es) 2013-05-23 2014-05-22 Metodos para la liberacion de cromolina.
MX2020013362A MX2020013362A (es) 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015016102A MX2015016102A (es) 2013-05-23 2014-05-22 Metodos para la liberacion de cromolina.

Country Status (9)

Country Link
US (1) US9861608B2 (es)
EP (1) EP2999337A4 (es)
JP (3) JP2016534976A (es)
CN (2) CN110652495A (es)
AU (4) AU2014284656B2 (es)
CA (1) CA2913235C (es)
HK (1) HK1218050A1 (es)
MX (2) MX2015016102A (es)
WO (1) WO2015002703A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN106102737B (zh) * 2013-10-22 2019-06-14 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
EP3104854B1 (en) 2014-02-10 2020-04-08 Respivant Sciences GmbH Mast cell stabilizers for lung disease treatment
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN108472393A (zh) * 2015-11-19 2018-08-31 阿尔茨治疗方法公司 用于治疗阿尔茨海默病和有关病症的方法
JP2018538273A (ja) * 2015-11-23 2018-12-27 エーゼットセラピーズ， インコーポレイテッド 虚血性脳卒中を処置するための組成物および方法
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018045217A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
WO2018071425A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111629719A (zh) * 2017-12-04 2020-09-04 通用医疗公司 色甘酸组合物及其方法
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation SODIUM CROMOGLYCATE AND ?-LACTOSE POWDER FORMULATIONS
AU2019336698A1 (en) * 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
US20220062222A1 (en) * 2018-12-10 2022-03-03 The General Hospital Corporation Cromolyn esters and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69027319T2 (de) * 1989-04-28 1996-11-21 Riker Laboratories Inc., Northridge, Calif. Inhalationsvorrichtung für trockenpulver
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989396A (en) 1997-04-02 1999-11-23 Eltech Systems Corporation Electrode and electrolytic cell containing same
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
BR9812693A (pt) * 1997-09-29 2000-08-22 Inhale Therapeutic Syst Uso de um agente bioativo, processo para formar uma microestrutura perfurada, microestrutura perfurada, processo para aumentar a dispersibilidade de um pó, pó de microestrutura perfurada, pó tendo dispersibilidade aumentada, sistema de inalação para a administração pulmonar de um agente bioativo a um paciente, e, processo para a liberação pulmonar de um ou mais agentes bioativos
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
US20040223918A1 (en) 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
JP5731406B2 (ja) * 2009-01-29 2015-06-10 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体、クロモリン誘導体を用いた治療方法及び造影方法
PL2248517T3 (pl) 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
CA3111941A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
JP2019073921A (ja) * 2017-10-17 2019-05-16 アイシン精機株式会社 車両用ドアチェック装置

Also Published As

Publication number Publication date
MX2015016102A (es) 2016-08-08
CA2913235C (en) 2021-07-13
EP2999337A1 (en) 2016-03-30
AU2014284656A2 (en) 2016-01-21
AU2019271898C1 (en) 2022-06-09
JP2016534976A (ja) 2016-11-10
HK1218050A1 (zh) 2017-02-03
US9861608B2 (en) 2018-01-09
JP2019112468A (ja) 2019-07-11
CA2913235A1 (en) 2015-01-08
AU2014284656A1 (en) 2016-01-21
AU2019271898B2 (en) 2022-02-03
US20160106704A1 (en) 2016-04-21
AU2022200260A1 (en) 2022-02-10
AU2017254974A1 (en) 2017-11-23
CN105377037A (zh) 2016-03-02
AU2014284656B2 (en) 2017-11-23
JP2021181493A (ja) 2021-11-25
EP2999337A4 (en) 2017-03-15
WO2015002703A1 (en) 2015-01-08
CN110652495A (zh) 2020-01-07
AU2019271898A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2020013362A (es) Metodos para la liberacion de cromolina.
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
HK1217439A1 (zh) 與毒性醛相關的疾病和治療
HK1220418A1 (zh) 治療呼吸系統疾病的方法及為此而製的製劑
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
HK1224184A1 (zh) 用於治療炎性疾病的化合物、藥物組合物和方法
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
MX2020005615A (es) Composiciones de cromolín y métodos de las mismas.
PL2922541T3 (pl) Hydrazony pirydylowe do leczenia gruźlicy i chorób pokrewnych
TH148448B (th) วิธีการสำหรับการบำบัดแก๊สปล่อย
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
UA88266U (ru) Способ комплексной профилактики и лечения поражений слизистой оболочки полости рта на фоне химиотерапии
GB201302884D0 (en) Novel methods for diagnosis and therapy
UA75671U (uk) Спосіб ступеневої інгаляційної терапії бронхолегеневої дисплазії у новонароджених